Effect of isoprenaline on plasma leptin and lipolysis in humans

Clin Endocrinol (Oxf). 1998 Apr;48(4):407-11. doi: 10.1046/j.1365-2265.1998.00480.x.

Abstract

Objective: The sympathetic nervous system may play a central role in the regulation of both lipolysis and leptin production. Therefore, we investigated the effect of intravenous infusions of the beta-adrenergic agonist isoprenaline on plasma concentrations of leptin and nonesterified fatty acids.

Design and patients: Eight lean, healthy human volunteers, (4M:4F; median (interquartile range) age 36.5 (30.8-40.0) years; BMI 22.9 (20.1-29.2) kg.m-2; % body fat 24.5 (17.9-26.3)), were studied following an overnight fast. Intravenous infusion of isoprenaline was carried out for 3 h, followed by a 1 hour recovery phase. The isoprenaline infusion rates (0.5-3.5 micrograms.min-1) were titrated individually for each subject in order to achieve similar biological sympathetic responses based on heart rate (target heart rates were > 100 min-1 but < twice resting heart rate).

Measurements: Plasma leptin was determined using an in-house radioimmunoassay, nonesterified fatty acids estimated with an enzymatic colourimetric assay and insulin concentrations were assayed using a specific, two-site immunoenzymometric assay.

Results: Fasting preinfusion plasma leptin concentrations (6.3 (3.0-12.8) micrograms/l) correlated with percentage body fat measured by bioimpedance (r = 0.95; P < 0.001). Plasma leptin concentrations were rapidly suppressed by isoprenaline, with maximal suppression (20.5 (15.0-25.0)% of preinfusion levels (Wilcoxon rank sum test; P < 0.05)), observed after 2 h. In the recovery period, plasma leptin concentrations rapidly returned to preinfusion levels (postinfusion vs maximally suppressed leptin concentrations P < 0.05; vs preinfusion leptin concentrations P = NS). Plasma nonesterified fatty acids and insulin concentrations showed opposite changes to those observed with leptin.

Conclusion: Plasma leptin concentrations are rapidly and reversibly suppressed by the infusion of isoprenaline in humans in vivo.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / administration & dosage*
  • Adrenergic beta-Agonists / pharmacology
  • Adult
  • Biomarkers / blood
  • Depression, Chemical
  • Fatty Acids, Nonesterified / blood*
  • Female
  • Humans
  • Infusions, Intravenous
  • Insulin / blood
  • Isoproterenol / administration & dosage*
  • Isoproterenol / pharmacology
  • Leptin
  • Lipolysis / drug effects
  • Male
  • Proteins / analysis*
  • Proteins / drug effects

Substances

  • Adrenergic beta-Agonists
  • Biomarkers
  • Fatty Acids, Nonesterified
  • Insulin
  • Leptin
  • Proteins
  • Isoproterenol